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Objectives. This study attempted to determine the benefit of a 
5-min dobutamine stress echocardiographic stage versus a 3-min 
stage in a canine model. 
Background. Dobutamine stress echocardiography, as cur- 
rently performed, uses a variety of different protocols. Among the 
many aspects of dobutamine stress echocardiographic protocols 
that vary is stage duration. Because dobutamine has specific 
pharmacodynamics, it is possible that stages of different dura- 
tions may have different cardiovascular effects. 
Methods. Paired dobutamine stress echocardiograms were ob- 
tained in 10 open chest instrumented dogs. The stage duration for 
the initial dobutamine stress echocardiogram was randomly allo- 
cated to either 3 or 5 rain, and all hemodynamic and echocardio- 
graphic variables were allowed to return to baseline before the 
second obutamine stress echocardiogram was obtained using the 
alternative stage duration. At each stage, heart rate, systolic blood 
pressure, coronary flow, myocardial wall thickness and left ven- 
tricular cavity area were recorded. Cavity obliteration, hypoten- 
sion, ventricular taehycardia or a maximal dose of 40 pg/kg body 
weight per min served as the dobutamine stress echocardio- 
graphic end point. 
Results. At baseline, no difference was detected between the 3- 
or 5-min protocols for heart rate, systolic blood pressure, rate- 
pressure product, coronary blood flow, wall thickness or percent 
area change. Heart rate, systolic blood pressure and coronary flow 
increased more by the 10-pg/kg per min dose with the 5-rain 
protocol than with the 3-min protocol. The dobutamine stress 
echocardiographic end points were achieved at a lower dobut- 
amine dose (15.0 -+ 4.1 vs. 11.0 -+ 2.1 pg/kg per rain [mean -+ SD], 
p = 0.01) with the longer stage duration. 
Conclusions. In this canine model, a longer stage produced a
greater hemodynamic effect at a lower peak dose. Thus, extending 
stage duration in clinical dobutamine stress echocardiography 
may achieve equivalent physiologic stress at lower doses and 
contribute to the optimization of dobutamine stress echocardio- 
graphic protocols. 
(J Am CoU Cardiol 1995;25:605-9) 
Dobutamine stress echocardiography is rapidly gaining accep- 
tance as a noninvasive method for evaluating myocardial 
ischemia; however, protocol standards vary. Many aspects of 
dobutamine stress echocardiographic protocols were devel- 
oped from practices used in exercise treadmill protocols with- 
out clear consideration or investigation of their physiologic 
implications. For example, dobutamine protocols most com- 
monly use 3-min stages of increasing dobutamine dose, but 
others have used 5- or 8-rain stages (1-3). The pharmacologic 
half-life of dobutamine is 2 min, with steady state not obtained 
for up to 10 rain (4,5). Thus, current stage durations would not 
be expected to achieve steady state at each dose. In addition, 
protocols utilizing different stage lengths may not be directly 
comparable. Before assessing the relative effectiveness of 
different stage durations of a dobutamine stress echocardio- 
gram to detect ischemia, the physiologic and hemodynamic 
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effects of the differing stage durations must be defined. There- 
fore, the purpose of this study was to determine whether the 
commonly used 3- and 5-rain dobutamine stress echocardio- 
graphic stage durations produce the same hemodynamic ef- 
fects and reach dobutamine stress echocardiographic end 
points at a similar dose. 
Methods  
Experimental model. Paired dobutaminc infusion proto- 
cols using 3- and 5-min stage durations were performed in 10 
mongrel dogs under continuous hemodynamic and echocardio- 
graphic surveillance. All animals were anesthetized with so- 
dium pentobarbital (30 mg/kg body weight) and mechanically 
ventilated throughout the study. Neither sedation or mechan- 
ical ventilation were altered just before or during a dobut- 
amine infusion. Through a midline sternotomy, the heart was 
suspended in a pericardial cradle. Invasive hemodynamic 
monitoring was obtained with a manometer-tipped catheter 
placed in the left ventricular cavity and a Doppler flow probe 
around an isolated portion of the proximal left anterior 
descending coronary artery. Continuous electrocardiography 
was performed using limb leads. 
Left ventricular systolic function was assessed throughout 
each dobutamine protocol with continuous two-dimensional 
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epicardial echocardiography and confirmed with sonomi- 
crometer crystals. Epicardial echocardiographic images of the 
midventricular cavity were recorded on 0.5-in. videotape using 
a 3.5-MHz transducer via a water bath. To obtain stable images 
of the midventricular cavity, visible internal andmarks (false 
tendons) defined the short-axis plane imaged during the 
infusion. Sonomicrometer piezoelectric crystals (2 to 4 mm, 
5 MHz) were placed in the endocardium and epicardial surface 
of the left ventricular apex and posterior wall to provide 
continuous measures of regional left ventricular wall thicken- 
ing. Proper alignment, calibration and synchronization were 
performed as previously outlined (6) and confirmed before 
commencing the dobutamine protocol. 
Dobutamine infusion. In all animals, dobutamine was in- 
fused in incremental doses of 5 p,g/kg per min using either a 3- 
or 5-rain stage duration. These stage durations were chosen 
because of their common use in clinical protocols. The infusion 
was begun at 5 p.g/kg per rain, then increased to a maximal 
dose of 40 ~kg per min. Once the dobutamine protocol was 
completed, no further dobutamine was infused for at least 
20 min to allow all hemodynamic variables to return to baseline 
values. A second dobutamine infusion was then performed 
using the alternative stage duration. To prevent potential bias, 
the first dobutamine infusion protocol in each dog was alter- 
nated between the 3- and 5-min stage duration. Hemodynamic 
variables and echocardiographic images were recorded at the 
end of each stage. 
Dobutamine infusion end points in this study were maximal 
dose of 40 p.g/kg per rain, hypotension (->20-mm Hg decrease 
in systolic pressure), ventricular tachycardia or complete sys- 
tolic midcavity obliteration. 
Echocardiographic analysis. At the completion of each 
study, end-systolic and end-diastolic midventricular short axis 
areas of the left ventricular cavity were measured using an 
off-line analysis ystem (SUM 1010, Sony Medical Electronics). 
All measurements were made in triplicate by a single observer 
who traced the inner edge of the ventricular endocardial 
border, including the papillary muscles and recorded the mean 
value. For the purpose of this study, end-systole was defined as 
the frame before ventricular expansion and end-diastole as the 
frame at or just before onset of the QRS complex. Finally, for 
the purpose of later analysis, midcavity obliteration was de- 
fined as a midventricular ea <1.0 cm 2 at end-systole. 
Statistical analysis. All results are expressed as mean 
value + SD. A paired, two-tailed Student  test was used to 
compare the baseline hemodynamic values before the different 
dobutamine infusions and the hemodynamic change at the 
10-/zg/kg per rain dose with the 3- or 5-rain dobutamine 
infusion protocol. A Bonferroni correction for multiple compar- 
isons was used to set an alpha value of 0.0125 for the paired ttests 
(7). 
Table 1. Baseline Hemodynamic Variables Before 
Dobutamine Infusion 
3-rain Stage 5-rain Stage p Value 
HR (heats/rain) 124.7 -+ 7.5 125.0 -+ 20.0 NS 
SBP (mm Hg) 117.5 +- 10.3 118.7 -- 17.5 NS 
HR x SBP 14,700 -+ 2,600 14,900 -+ 3,500 NS 
Cor flow (ml/min) 18.4 _+ 7.5 19.1 _+ 8.7 NS 
% Area change 61.9 _+ 12.6 59.9 +_ 17.2 NS 
Data presented are mean value + SD. Cot flow = left anterior descending 
coronary artery, blood flow; HR - heart rate; SBP = systolic blood pressure; % 
area change - percent area change in left ventricular cross-sectional area at the 
papillary, muscle level. 
flow) and left ventricular percent area change were no different 
before each infusion protocol for each dog. This held true 
regardless of which infusion protocol was performed first. 
Differing hemodynamic effects of each dobutamine infusion 
protocol. With the graded infusion of dobutamine in 3- or 
5-min stages, there was an increase in mean heart rate, systolic 
blood pressure, coronary flow and left ventricular systolic 
function, as assessed by both echocardiography and sonomi- 
crometry (p < 0.05). Coronary flow had the greatest change 
from baseline. All variables were significantly increased from 
predobutamine levels by the 10-~g/kg per min dose regardless 
of stage duration. However, the rate of increase of these 
variables differed with different infusion stage durations. 
During the 5-min infusions, there was a greater ate of 
increase by the 10-/~g/kg per rain stage in heart rate, systolic 
blood pressure, coronary flow and percent left ventricular area 
change than with the 3-min infusions (Fig. 1). Hemodynamic 
values at the 10-/zg/kg per rain dose for the 3- and 5-rain 
protocols for heart rate were 139.0 _+ 20.7 versus 155.6 +_ 22.7 
beats/min, systolic blood pressure 136.5 + 26.7 versus 152.7 _+ 
22.9 mm Hg, coronary flow 28.1 + 11.9 versus 43.4 _+ 
12.9 ml/min and percent area change 77.3 _+ 24.4% versus 
92.1 _+ 6.8%, respectively. 
Stage duration altering termination dose. In all 20 dobut- 
amine infusions, the tests were terminated because of left 
ventricular cavity obliteration. There were no episodes of 
ventricular tachycardia or hypotension. Dobutamine infusion 
end points were reached at a lower peak dose with the 5-min 
stages in 6 of 10 dogs and at the same dose in the other 4 dogs 
(Fig. 2). Thus, dobutamine end points were obtained at a mean 
lower peak dose (15.0 _+ 4.1 vs. 11.0 _+ 2.1 t~g/kg per rain, p = 
0.01) with the longer stage duration. Although the protocol 
with longer stage duration infuses more dobutamine for each 
stage, the total cumulative dobutamine administered to reach 
an end point in the 3- and 5-minute protocols was not different 
(94.5 _+ 43.0 vs. 90.0 _+ 31.6 p~g/kg per min, p = NS) owing to 
the differences in termination point. 
Resu l ts  
Baseline hemodynamic variables (Table 1). Baseline he- 
modynamic variables (heart rate, blood pressure, coronary 
Discuss ion  
Examination of the effect of different dobutamine stress 
echocardiographic protocols requires the performance of 
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Figure 1. Graphs demonstrating the percent change (mean _+ SD) 
from baseline values at each dose of dobutamine for the 3- and 5-min 
protocols. A, Heart rate (HR). B, Systolic blood pressure (SBP). C, 
Left anterior descending coronary artery flow (COR FLOW). D, Left 
ventricular cross-sectional area change at the papillary level (%AC). 
There is a greater increase in each variable with the 5-min than the 
3-min protocol at the 10-~g/kg per min dose. *p -< 0.01. 
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Figure 2. Peak dobutamine dose at which dobutaminc stress cchocar- 
diographic end points were obtained for each dog using the 3- and 
5-rain protocols. Dobutamine infusion end points were reached at a 
lower peak dose with the 5-rain stages in 6 of 10 dogs and at the same 
dose in the other 4 dogs. Dobutamine end points were therefore 
obtained at a lower mean peak dose (15.0 _+ 4.1 vs. 11.0 + 2.1 ~g/kg 
per rain, p = 0.01) with the longer stage duration. 
paired studies. Such clinical protocols are difficult to perform, 
and thus direct comparisons of the physiologic and hemody- 
namic effects of differing dobutamine stress echocardiographic 
stage durations, to our knowledge, have previously not been 
accomplished. Obtaining paired dobutamine stress echocar- 
diograms in a canine model to compare different stage dura- 
tions demonstrates that longer stage duration results in 1) a 
greater increase in hemodynamic variables for a comparable 
infusion rate, and 2) achievement of dobutamine stress echo- 
cardiographic end points at an earlier stage that corresponds to 
a lower peak dose. Although this study was performed in a 
nonischemic anine model to establish a pharmacologic bases 
for future clinical studies, these findings suggest that the 
kinetics of the agent used in pharmacologic stress echocardi- 
ography will influence the timing of its effect. 
Many aspects of dobutamine stress echocardiographic pro- 
tocols have evolved from the commonly used exercise treadmill 
and exercise echocardiographic protocols (8-10). Exercise 
induces myocardial ischemia in the setting of a fixed stenosis by 
increasing myocardial oxygen demand primarily through an 
increase in heart rate and blood pressure. The increased 
myocardial oxygen demand reaches steady state at each new 
level of exercise in -5  rain (11). Because exercise tests that last 
>20 rain introduce potentially confounding variables, such as 
internal heat burden, a practical compromise has developed in 
which exercise stages are advanced every 3 rain to obtain a 
predicted maximal heart rate (8). 
However, the results of the present study suggest that 
adapting this same 3-min convention for dobutamine echocar- 
diography may not be optimal. Utilizing increasing, graded 
doses of dobutamine has been shown to be a safe method of 
infusing an inotropic drug in patients with coronary artery 
disease (1). Although a variety of stage durations were initially 
used, the 3-min protocol has become the most popular. In an 
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attempt to obtain target heart rates similar to those obtained 
with exercise stress tests, it became necessary to give increasing 
doses of dobutamine. Most centers will infuse up to 40/~g/kg 
per rain of dobutamine, whereas others now infuse 50/~g/kg 
per rain and add atropine to further increase the heart rate (1). 
Such approaches fail to recognize and utilize the pharmacoki- 
netic data accumulated for these agents. Dobutamine has a 
half-life of 2 rain, with steady state not obtained for up to 
10 rain. Thus, a 3-rain stage is insutficient time to reach the full 
cardiovascular effect of a dobutamine dose. For those applying 
dobutamine stress echocardiography for the detection of myo- 
cardial viability, this has become apparent, and the evolving 
convention isto prolong the low dose infusion for 5 to 10 min 
(12). Nonetheless, few have adapted these longer stage dura- 
tions for the entirety of the dobutamine stress echocardiogram. 
Clinical implications of prolonged stage duration. A 
longer stage duration may have a number of potential benefits, 
including improved test accuracy, decreased need for atropine, 
lower termination dose and enhanced assessment ofviability. 
Although study designs and results vary, the sensitivity and 
specificity of dobutamine stress echocardiography in detecting 
significant coronary artery disease range from 75% to 95% and 
66% to 95%, respectively (13-16). Although a maximal dobut- 
amine dose of 40 /~g/kg per rain is a common dobutamine 
stress echocardiographic end point, some patients (especially 
those taking beta-adrenergic blocking agents) may not exhibit 
a significant hemodynamic response at this dose (17-21). In 
this situation, patients with mild or moderate coronary steno- 
ses may not develop a new wall motion abnormality with a 
short stage duration but may demonstrate the abnormality with 
the increased myocardial oxygen demand induced with the 
longer stage duration. Thus, the sensitivity of this test for 
detecting coronary artery disease might be improved, espe- 
cially in patients with a moderate pretest probability of coro- 
nary artery disease or those taking beta-blockers. 
If the inotropic response, heart rate and blood pressure are 
responsible for the induction of myocardial ischemia, then 
changes in stage duration may alter the dose at which a 
dobutamine stress echocardiogram is terminated. This might 
result in fewer of the mild drug effects currently observed at 
high doses (1) and alleviate concerns of administering very 
high doses of dobutamine in patients with significant coronary 
artery disease. More important, because the longer stage 
durations result in further chronotropic stimulation, the com- 
monly used end point of 85% maximal predicted heart rate 
would be reached in a higher proportion of patients, and the 
need for atropine may be reduced or eliminated. Recovery of 
regional myocardial function at low doses of dobutamine (4to 
10 /~g/kg per rain) correlates with metabolically active and 
viable myocardium. In the present study, even at the 10-t~g/kg 
per rain dose, greater improvements in coronary flow were 
noted during 5-rain stage durations. If this is critical to the 
assessment of viability, again the ability of the test to detect 
viable segments might be improved by the increase in stage 
duration. Further studies are required to test these potential 
implications. 
Importance of standardization of dobutamine stress echo- 
cardiography protocols. As dobutamine stress echocardiogra- 
phy becomes more widespread and as new pharmacologic 
stress agents are developed, the need for standardization a d 
ability to compare results across tests becomes more impor- 
tant. The data from this study suggest that small changes in the 
dobutamine stress echocardiography protocol, such as alter- 
ation in stage duration, could change the final interpretation f 
the test. A patient with mild or moderate coronary disease 
might have negative dobutamine stress echocardiographic re- 
sults under one protocol but an induced wall motion abnor- 
mality under a more intensive protocol. Institutions with 
aggressive protocols using higher dobutamine doses or addi- 
tional agents may find a higher rate of adverse ffects than 
those with a more conservative protocol. In addition, if the 
dose at which a new wall notion abnormality develops imparts 
diagnostic or prognostic information, then the need for stage 
duration standardization becomes particularly important. Fi- 
nally, as new agents are developed that more rapidly or 
selectively induce myocardial ischemia, itwill be important to 
examine their time- and dose-related hemodynamic effects to 
optimize the stage durations for these agents. For example, 
arbutamine, a new synthetic nonselective beta-agonist with 
significant alpha-adrenoreceptor affinity has been applied to 
stress echocardiography and has unique pharmacokinetics 
(22). By quantitating the time- and dose-related hemodynamic 
effects of each agent, it may be possible to compare the results 
of one agent with those of another. 
Study limitations. There are potential limitations in the 
clinical application of these results. 1) The open chest model 
may alter hemodynamic response and dose at which dobut- 
amine stress echocardiographic end points were obtained. In 
the open chest, open pericardium canine heart there are 
alterations in the normal pressure-volume relation without 
adverse influence on contractility (23,24). All confounding 
effects of the open chest model, such as anesthesia, sedation 
and mechanical ventilation, were controlled for in this paired 
study. Many of the early studies of dobutamine effects on the 
cardiovascular system were performed in similar open chest 
canine models before confirmation of these effects in the 
clinical setting (25,26). Thus whether the dobutamine stress 
echocardiogram is obtained in an open or closed chest model, 
the influences and effects observed in this study may similarly 
have clinical application. 2) A canine heart is anatomically 
different from the human heart. The ratio of myocardial wall 
thickness to cavity diameter is larger in the canine heart, thus 
simulating concentric hypertrophy. In addition, none of the 
dogs had significant coronary artery disease, which excluded 
the likelihood of extensive wall motion abnormalities with 
dobutamine infusion. For these reasons, this canine model was 
primed for cavity obliteration during vigorous inotropic stim- 
ulation, which accounts for the high incidence (100%) ob- 
served in this study. Because of these anatomic differences and 
the lack of coronary stenoses, the application of a longer stage 
duration must be examined in the clinical setting to assess its 
application to more common clinical dobutamine stress echo- 
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cardiographic end points, such as the onset of a new wall 
motion abnormality. 
Conclusions. Although dobutamine stress echocardiogra- 
phy is rapidly being used in the clinical setting, fundamental 
aspects of the protocol should be reexamined to further 
optimize the sensitivity, specificity and predictive value of the 
examination while minimizing the adverse ffects. The phar- 
macodynamics of dobutamine and the results of this study 
support longer stage durations than those used in exercise 
stress testing. The longer duration produces a greater cardio- 
vascular response at a lower peak dobutamine dose and has the 
potential to increase the sensitivity of a dobutamine stress 
echocardiogram while avoiding the need for additional phar- 
macologic agents and lowering the incidence of adverse vents. 
We thank John B. Newell, BS for assistance with the statistical analysis and Tracy 
Svizzero, BS for technical assistance. 
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